ARTICLE | Finance
Europe: Picking out the winners
October 1, 2001 7:00 AM UTC
3Q Financial Review
It is impossible to guess when the downturn in European biotech stocks will end. But end it will. And arguably the sector will come out the other side in better shape, as a sufficiently long drought will shake out the weaker public companies. At the same time, if the IPO market remains closed for a significant period, private companies will have a chance to mature using venture money, which ultimately would give public equity investors larger, more advanced companies in which to invest...